Ashton, Nicholas J.

Fluid Biomarkers for Synaptic Dysfunction and Loss

Camporesi, E., Nilsson, J., Brinkmalm, A., Becker, B., Ashton, N. J., Blennow, K., & Zetterberg, H. (2020) · Biomarker Insights

Alzheimer's disease research and treatmentsNeuroscience and Neuropharmacology Research

Cited by 165

Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies

Mattsson-Carlgren, N., Collij, L. E., Stomrud, E., Pichet Binette, A., Ossenkoppele, R., Smith, R., Karlsson, L., Lantero-Rodriguez, J., Snellman, A., Strandberg, O., et al. (2024) · JAMA Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 148

Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid

Gobom, J., Parnetti, L., Rosa-Neto, P., Vyhnalek, M., Gauthier, S., Cataldi, S., Lerch, O., Laczo, J., Cechova, K., Clarin, M., et al. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM)

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 146

Head‐to‐head comparison of clinical performance of CSF phospho‐tau T181 and T217 biomarkers for Alzheimer's disease diagnosis

Karikari, T. K., Emeršič, A., Vrillon, A., Lantero‐Rodriguez, J., Ashton, N. J., Kramberger, M. G., Dumurgier, J., Hourregue, C., Čučnik, S., Brinkmalm, G., et al. (2021) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 143

The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers

Ashton, N. J., Leuzy, A., Karikari, T. K., Mattsson-Carlgren, N., Dodich, A., Boccardi, M., Corre, J., Drzezga, A., Nordberg, A., Ossenkoppele, R., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 142

Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability

Therriault, J., Janelidze, S., Benedet, A. L., Ashton, N. J., Arranz Martínez, J., Gonzalez-Escalante, A., Bellaver, B., Alcolea, D., Vrillon, A., Karim, H., et al. (2024) · Nature Aging

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 131

Astrocyte biomarkers GFAP and YKL‐40 mediate early Alzheimer's disease progression

Pelkmans, W., Shekari, M., Brugulat‐Serrat, A., Sánchez‐Benavides, G., Minguillón, C., Fauria, K., Molinuevo, J. L., Grau‐Rivera, O., González Escalante, A., Kollmorgen, G., et al. (2024) · Alzheimer's & Dementia

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 122

Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies.

Montoliu-Gaya, L., Benedet, A. L., Tissot, C., Vrillon, A., Ashton, N. J., Brum, W. S., Lantero-Rodriguez, J., Stevenson, J., Nilsson, J., Sauer, M., et al. (2023) · Nature Aging

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 122

Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer’s disease: a longitudinal cohort study

O’Connor, A., Karikari, T. K., Poole, T., Ashton, N. J., Lantero Rodriguez, J., Khatun, A., Swift, I., Heslegrave, A. J., Abel, E., Chung, E., et al. (2021) · Molecular Psychiatry

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 122

Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar Degeneration

Benussi, A., Ashton, N. J., Karikari, T. K., Gazzina, S., Premi, E., Benussi, L., Ghidoni, R., Rodriguez, J. L., Emeršič, A., Binetti, G., et al. (2020) · Journal of Alzheimer’s Disease

Dementia and Cognitive Impairment ResearchAmyotrophic Lateral Sclerosis Research

Cited by 113

Population-based blood screening for pre-clinical Alzheimer’s disease: a British birth cohort at age 70

Keshavan, A., Pannee, J., Karikari, T. K., Rodriguez, J. L., Ashton, N. J., Nicholas, J. M., Cash, D. M., Coath, W., & Lane, C. A. (2022) · Journal of Neurology, Neurosurgery & Psychiatry

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 94

Brain injury in COVID-19 is associated with dysregulated innate and adaptive immune responses

Needham, E. J., Ren, A. L., Digby, R. J., Norton, E. J., Ebrahimi, S., Outtrim, J. G., Chatfield, D. A., Manktelow, A. E., Leibowitz, M. M., Newcombe, V. F. J., et al. (2022) · Brain

Long-Term Effects of COVID-19COVID-19 Clinical Research Studies

Cited by 90

Salivary Biomarkers for Alzheimer’s Disease and Related Disorders

Ashton, N. J., Ide, M., Zetterberg, H., & Blennow, K. (2019) · Neurology and Therapy

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 89

Comparing Glial Fibrillary Acidic Protein (GFAP) in Serum and Plasma Following Mild Traumatic Brain Injury in Older Adults

Huebschmann, N. A., Luoto, T. M., Karr, J. E., Berghem, K., Blennow, K., Zetterberg, H., Ashton, N. J., Simrén, J., Posti, J. P., Gill, J. M., et al. (2020) · Frontiers in Neurology

Traumatic Brain Injury ResearchTraumatic Brain Injury and Neurovascular Disturbances

Cited by 85

Blood–brain barrier opening of the default mode network in Alzheimer’s disease with magnetic resonance-guided focused ultrasound

Meng, Y., Goubran, M., Rabin, J. S., McSweeney, M., Ottoy, J., Pople, C. B., Huang, Y., Storace, A., Ozzoude, M., Bethune, A., et al. (2023) · Brain

Ultrasound and Hyperthermia ApplicationsBarrier Structure and Function Studies

Cited by 83

Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease

Nilsson, J., Gobom, J., Sjödin, S., Brinkmalm, G., Ashton, N. J., Svensson, J., Johansson, P., Portelius, E., Zetterberg, H., Blennow, K., et al. (2021) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 82

APOE ε4 associates with microglial activation independently of Aβ plaques and tau tangles

Ferrari-Souza, J. P., Lussier, F. Z., Leffa, D. T., Therriault, J., Tissot, C., Bellaver, B., Ferreira, P. C. L., Malpetti, M., Wang, Y.-T., Povala, G., et al. (2023) · Science Advances

Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 81

Synaptic vesicle protein 2A as a potential biomarker in synaptopathies

Heurling, K., Ashton, N. J., Leuzy, A., Zimmer, E. R., Blennow, K., Zetterberg, H., Eriksson, J., Lubberink, M., & Schöll, M. (2019) · Molecular and Cellular Neuroscience

Alzheimer's disease research and treatmentsNeuroscience and Neuropharmacology Research

Cited by 77

Diagnostic value of serum versus plasma phospho-tau for Alzheimer’s disease

Kac, P. R., Gonzalez-Ortiz, F., Simrén, J., Dewit, N., Vanmechelen, E., Zetterberg, H., Blennow, K., Ashton, N. J., & Karikari, T. K. (2022) · Alzheimer's Research & Therapy

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 73

Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer’s disease in adults with Down syndrome

Lleó, A., Zetterberg, H., Pegueroles, J., Karikari, T. K., Carmona-Iragui, M., Ashton, N. J., Montal, V., Barroeta, I., Lantero-Rodríguez, J., Videla, L., et al. (2021) · Nature Communications

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 72

Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease

Picard, C., Nilsson, N., Labonté, A., Auld, D., Rosa‐Neto, P., Initiative, T. A. D. N., Ashton, N. J., Zetterberg, H., Blennow, K., Breitner, J. C. B., et al. (2022) · Alzheimer's & Dementia

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 66

Hippocampal GFAP-positive astrocyte responses to amyloid and tau pathologies

De Bastiani, M. A., Bellaver, B., Brum, W. S., Souza, D. G., Ferreira, P. C. L., Rocha, A. S., Povala, G., Ferrari-Souza, J. P., Benedet, A. L., Ashton, N. J., et al. (2023) · Brain, Behavior, and Immunity

Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 57

Association of plasma P-tau181 with memory decline in non-demented adults

Therriault, J., Benedet, A. L., Pascoal, T. A., Lussier, F. Z., Tissot, C., Karikari, T. K., Ashton, N. J., Chamoun, M., Bezgin, G., Mathotaarachchi, S., et al. (2021) · Brain Communications

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 56

Amyloid processing in COVID‐19‐associated neurological syndromes

Ziff, O. J., Ashton, N. J., Mehta, P. R., Brown, R., Athauda, D., Heaney, J., Heslegrave, A. J., Benedet, A. L., Blennow, K., Checkley, A. M., et al. (2022) · Journal of Neurochemistry

Long-Term Effects of COVID-19Infectious Encephalopathies and Encephalitis

Cited by 54